🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Optimising first-line subtyping-based therapy in triple-negative #breast #cancer #TNBC (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial. Very intriguing results! ⁦OncoAlert⁩ thelancet.com/journals/lanon…

70-Gene Signature ❌NOT independently predictive of LRR. Cannot be used in clinical decision making regarding LRR #Breastcancer ⁦OncoAlert⁩ ascopubs.org/doi/10.1200/JC…

Amazing Results 1L #mCRC #MSI-H/dMMR #NIVO/IPI

Primary surgery was an inferior ❌strategy vs preoperative CRT ☢️ followed by surgery, in LARC with MRI-negative MRF. It cannot be recommended in the clinical practice #rectal #cancer ⁦OncoAlert⁩ redjournal.org/article/S0360-…

Treatment with doxorubicin is associated with increased #Breastcancer risk in both adolescent and adult #Hodgkin #Lymphoma survivors ➡️ very long follow-up for survivors of HL needed ⁦AIRO Breast Cancer Group⁩ ascopubs.org/doi/10.1200/JC…

Despite 5 yr follow-up, most #cancer #drugs granted accelerated approval did not demonstrate benefit in #OS or QoL in confirmatory trials #JAMA jamanetwork.com/journals/jama/…

Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study: ⭕️Final CLEAR trial results: Lenvatinib+pembrolizumab reduces mortality risk by 21% vs sunitinib in advanced RCC. ⭕️While median OS is similar, the combo’s lower HR & tight 95% CI underscore its robust

Multidisciplinary Management of Soft Tissue #Sarcoma of the Extremity and Trunk. #cancer #guidelines #ASCO ascopubs.org/doi/10.1200/OP…

It is a great pleausure to know early the results of IRMA trial which will be presented next evening by one of my best friend and colleague at ESTRO 24. Stay tuned!!!!#ESTRO24 Bruno Meduri

It has been a pleasure and an honor to report the 5-year results of #IRMA #trial at #ESTRO2024 - #APBI is not inferior to WBI in low risk #BreastCancer

Stay tuned! Soon the full paper with additional data #IRMA #trial #PBI #BreastCancer

Packed room for a great kickoff! youngAIRO #AIRO2024

💥 excellent presentations given by 🔝speakers #AIRB plenary session 👏 Pierluigi Bonomo Bruno Meduri marta scorsetti Giorgia Timon, Francesco Cellini

La Regione #EmiliaRomagna si dota in radioterapia oncologica di un altro macchinario all’avanguardia! Unica #Cyberknife in RER, brava Elisa D’Angelo e buon lavoro! ⁩ #RadOnc

📌 Dose constraints in breast cancer radiotherapy. A critical review sciencedirect.com/science/articl… 👉🏻 This narrative review provides a comprehensive summary that may help to harmonize treatment planning strategies.☢️✔️ OncoAlert #OncoAlertAF Maria Carmen De Santis Bruno Meduri Fiorenza De Rose

Dose constraints in #radiotherapy #BreastCancer ⛔️ all OARs ☢️ different fractionation schedules 🩺 proposed DVCs correlated with clinical endpoints #RadOnc for a 50 days' free access 👇🏼 authors.elsevier.com/c/1j-vNcA0-Idri

Role of ☢️ #radiotherapy in the multidisciplinary management of #male #breastcancer #oncoalert #radonc 👇🏼 doi.org/10.1016/j.crit…

Tumor #microenvironment of #SCLC is often 🧊❄️ A review of new clinical targets #lungcancer #immunotherapy aacrjournals.org/clincancerres/…

#SONIA trial: CDK4/6i first-line vs second-line treatment 👇🏼 ⛔️ No statistically significant benefit for the use of CDK4/6i as a first-line 1️⃣ First line 👇🏼 💵 more cost ⚠️ more G3-4 adverse events #Breast #Cancer ⁦OncoAlert⁩ nature.com/articles/s4158…

❗️‼️🚨 SKAGEN-1 Breast cancer specific mortality HR 1.44 (1.05-1.97) in favor of 25 fx rather than 15 fx!! Less trips to the clinic vs survival benefit - not a difficult choice, is it folks? #ESTRO25